Evidence from randomised trials on the long-term effects of hormone replacement therapy

Lancet

Volumn 360, Issue 9337, 2002, Pages 942-944

  Beral, Valerie ^a,b   Banks, Emily ^a   Reeves, Gillian ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b RADCLIFFE INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN;

AGE; BREAST CANCER; CANCER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COLORECTAL CANCER; DRUG SAFETY; ENDOMETRIUM CANCER; FEMALE; FEMUR FRACTURE; HORMONE SUBSTITUTION; HUMAN; INCIDENCE; LUNG EMBOLISM; MENOPAUSAL SYNDROME; OVARY CANCER; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; STROKE;

EID: 0037152096     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)11032-4     Document Type: Short Survey

References (17)

1. Beral V., Banks E., Reeves G., Appleby A. Use of HRT and the subsequent risk of cancer. J Epidemiol Biostat. 4:1999;191-215.
2. Writing Group for the Women's Health Initiative Investigators . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 288:2002;321-333.
3. Hulley S., Grady D., Bush T., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 280:1998;605-613.
4. Heart and Estrogen/progestin Replacement Study Follow-up (HERS II), Grady D., Herrington D., Bittner V. Cardiovascular disease outcomes during 6.8 years of hormone therapy. JAMA. 288:2002;49-57.
5. Heart and Estrogen/progestin Replacement Study Follow-up (HERS II), Hulley S., Furberg C., Barrett-Connor E. Noncardiovascular disease outcomes during 6.8 years or hormone therapy. JAMA. 288:2002;58-66.
6. HERS Research Group, Simon J.A., Hsia J., Cauley J.A. Postmenopausal hormone therapy and risk of stroke: the Heart and Estrogen-progestin Replacement Study (HERS). Circulation. 103:2001;638-642.
7. Hoibraaten E., Qvigstad E., Arnesen H., Larsen S., Wickstrom E., Sandset P.M. Increased risk of recurrent venous thromboembolism during hormone replacement therapy: results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Thromb Haemost. 84:2000;961-967.
8. Viscoli C.M., Brass L.M., Kernan W.N., Sarrel P.M., Suissa S., Horwitz R.I. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med. 345:2001;1243-1249.
9. Kahn M.A., Heagerty A.M., Kitchener H., McNamee R., Cherry N.M., Hannaford P. Oestrogen and women's heart disease. Q J Med. 93:2000;699-702.
10. Vickers M.R., Collins N. Progress on the WISDOM trial - Women's International Study of long duration oestrogen after the menopause. Climacteric. 5:(suppl 1):2002;133-134.
11. The Women's Health Initiative Study Group . Design of the Women's Health Initiative Clinical Trial and Observational Study. Control Clin Trials. 19:1998;61-109.
12. Collaborative Group on Hormonal Factors in Breast Cancer . Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet. 350:1997;1047-1059.
13. Meade T.W., Vickers M.R. HRT and cardiovascular disease. J Epidemiol Biostat. 4:1999;165-190.
14. Weiss N.S., Ure C.L., Ballard J.H., Williams A.R., Daling J.R. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of oestrogen. N Engl J Med. 303:1980;1195-1198.
15. Alzheimer's Disease Collaborative Study, Mulnard R.A., Cotman C.W., Kawas C. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled study. JAMA. 283:2000;1007-1015.
16. HERS Research Group, Hlatky M.A., Boothroyd D., Vittinghoff E. Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/Progestin Replacement Study (HERS) Trial. JAMA. 287:2002;591-597.
17. Lacey J.V., Mink P.J., Lubin J.H., et al. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA. 288:2002;334-341.